1220973-40-9

Upstream product

• 1220973-38-5 N-hydroxy-3-iodo-4-isopropoxybenzimidamide 
• 76327-32-7 3-chloro-4-propoxybenzoic acid 
• 1220973-39-6 3-iodo-4-isopropoxybenzonitrile 

Downstream Products

• 1220973-41-0 4-(5-(3-chloro-4-propoxyphenyl)-1,2,4-oxadiazol-3-yl)-2-iodophenol 
• 1220973-37-4 2-amino-2-(5-(5-(3-chloro-4-propoxyphenyl)-1,2,4-oxadiazol-3-yl)benzofuran-2-yl)propane-1,3-diol 
• 1220973-42-1 tert-butyl N-[5-[5-[5-(3-chloro-4-propoxy-phenyl)-1,2,4-oxadiazol-3-yl]benzofuran-2-yl]-2,2-dimethyl-1,3-dioxan-5-yl]carbamate 

Relevant academic research and scientific papers

ORGANIC COMPOUNDS

Novel benzofuran derivatives are disclosed. The derivatives have S1P1 receptor activity and/or disease modifying activity and find use in the treatment of conditions or diseases associated with the immune, vascular and nervous systems in animals and/or humans

S1P RECEPTORS MODULATORS AND THEIR USE THEREOF

The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.